Article
Cardiac & Cardiovascular Systems
Gemma A. Figtree, Keith Broadfoot, Barbara Casadei, Robert Califf, Filippo Crea, Grant R. Drummond, Jane E. Freedman, Tomasz J. Guzik, David Harrison, Derek J. Hausenloy, Joseph A. Hill, James L. Januzzi, Bronwyn A. Kingwell, Carolyn S. P. Lam, Calum A. MacRae, Frank Misselwitz, Tetsuji Miura, Rebecca H. Ritchie, Maciej Tomaszewski, Joseph C. Wu, Junjie Xiao, Faiez Zannad
Summary: The development of new approaches for discovering and implementing new therapies is crucial in addressing the substantial gaps in pharmacotherapy for common forms of cardiovascular disease. Improved phenotyping of patients and unbiased 'omic' approaches can help in discovering new mechanisms and targeting specific biological mechanisms. Reimagining the relationships among discovery, translation, evaluation, and implementation will help establish innovative platforms and approaches in therapeutic development for cardiovascular diseases.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Deewa Zahir, Anders Bonde, Christian Madelaire, Morten Malmborg, Jawad H. Butt, Emil Fosbol, Gunnar Gislason, Christian Torp-Pedersen, Charlotte Andersson, Patrick Rossignol, John J. McMurray, Lars Kober, Morten Schou
Summary: This study investigated the temporal trends in the initiation, withdrawal, and adherence of mineralocorticoid receptor antagonists (MRA) in heart failure (HF) patients in Denmark. The findings revealed that approximately half of the patients initiated MRA therapy within 6 months after diagnosis, but approximately half of them withdrew from MRA treatment within 5 years. These findings underscore the importance of focusing on the retention of MRA treatment in real-life clinical practice.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Article
Cardiac & Cardiovascular Systems
Caroline H. Garred, Deewa Zahir, Jawad H. Butt, Pauline B. Ravn, Jonas Bruhn, Gunnar H. Gislason, Emil L. Fosbol, Christian Torp-Pedersen, Mark C. Petrie, John J. V. McMurray, Lars Kober, Morten Schou
Summary: This study found that advancing age is associated with lower adherence and higher discontinuation rates of ACEi/ARB and BBs in patients with heart failure. Paying attention to treatment adherence and optimal dosages among elderly patients with heart failure could improve outcomes.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Medicine, General & Internal
Yaar S. Aga, Sumant P. Radhoe, Dilan Aydin, G. C. M. Linssen, Philip C. Rademaker, Peter R. Geerlings, Marco W. F. van Gent, Ismail Aksoy, Liane Oosterom, Hans-Peter Brunner-La Rocca, Bas M. van Dalen, Jasper J. Brugts
Summary: This study aimed to evaluate heart failure treatment in a large real-world Western European cohort with and without obesity. The results showed that obese patients were more frequently prescribed guideline-recommended medications at higher doses.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2023)
Review
Cardiac & Cardiovascular Systems
Roberto C. Cerrud-Rodriguez, Daniel Burkhoff, Azeem Latib, Juan F. Granada
Summary: Chronic heart failure is a debilitating chronic condition that affects millions of people worldwide and imposes a significant financial burden on healthcare systems. Despite advances in therapy, morbidity and mortality rates remain high. This paper provides a technical overview of catheter-based interventional therapies currently under clinical investigation, targeting various physiological and anatomical points.
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2022)
Review
Medicine, General & Internal
Biagio Castaldi, Elena Cuppini, Jennifer Fumanelli, Angela Di Candia, Jolanda Sabatino, Domenico Sirico, Vladimiro Vida, Massimo Padalino, Giovanni Di Salvo
Summary: Pediatric heart failure is a clinically important condition with high morbidity and mortality. It differs from adult heart failure in terms of etiology, physiology, clinical course, and therapeutic approaches. New drugs and non-pharmacological therapies have been developed to identify personalized treatment regimens. This article reviews the potential new drugs and non-pharmacological therapies for pediatric heart failure.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Roberto Spoladore, Giulio Falasconi, Giorgio Fiore, Silvana Di Maio, Alberto Preda, Massimo Slavich, Alberto Margonato, Gabriele Fragasso
Summary: Myocardial fibrosis is a dynamic process with potential therapeutic targets such as TGF-beta, cTGF, and Gal-3. Clinical practice involves drugs with anti-fibrotic properties, while preclinical studies show promise for new drugs in targeting cardiac fibrosis and improving left ventricular function. However, there is a lack of clinical trials and engineered molecules for specific targets in this field.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Medicine, General & Internal
Vincenzo De Marzo, Gianluigi Savarese, Lucia Tricarico, Sofia Hassan, Massimo Iacoviello, Italo Porto, Pietro Ameri
Summary: Combination medical therapy including neurohormonal inhibitors and newer drugs, especially ARNI and SGLT2i, confers the maximum benefit with regard to HFrEF prognosis.
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Camilla Fuchs Andersen, Massar Omar, Andreas Glenthoj, Daniel El Fassi, Holger J. Moller, Jorgen A. Lindholm Kurtzhals, Bjarne Styrishave, Caroline Kistorp, Christian Tuxen, Mikael K. Poulsen, Jens Faber, Lars Kober, Finn Gustafsson, Jacob E. Moller, Morten Schou, Jesper Jensen
Summary: This study aimed to investigate the early effect of empagliflozin on erythropoiesis and iron metabolism in patients with heart failure with reduced ejection fraction. The results showed that empagliflozin increased erythropoiesis and enhanced early iron utilization, which may contribute to the cardioprotective properties of empagliflozin.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Joyce N. Njoroge, John R. Teerlink
Summary: ADHF is a leading admission diagnosis worldwide, with incompletely understood pathophysiology and limited therapeutic options. Patients often experience high in-hospital morbidity and mortality due to suboptimal medical management leading to persistent congestion upon hospital discharge and inadequate initiation of life-saving therapies before discharge. There has been no new therapy approved for ADHF in decades, highlighting the need for expanding available therapies for these high-risk patients.
CIRCULATION RESEARCH
(2021)
Article
Cell Biology
Tomi Tuomainen, Nikolay Naumenko, Maija Mutikainen, Anastasia Shakirzyanova, Sarah Sczelecki, Jennifer L. Estall, Jorge L. Ruas, Pasi Tavi
Summary: Non-canonical isoforms of PGC-1 alpha are expressed in the heart and can induce specific cardiac phenotypes through cellular signaling pathways. These findings reveal the different biological roles of PGC-1 alpha isoforms, which should be taken into account in future therapeutic developments.
Article
Cardiac & Cardiovascular Systems
Domenico D'Amario, Daniele Rodolico, Giuseppe M. C. Rosano, Ulf Dahlstrom, Filippo Crea, Lars H. Lund, Gianluigi Savarese
Summary: Heart failure patients with reduced ejection fraction who use higher doses of RASi or ARNi and beta-blockers have a lower risk of cardiovascular death or HF hospitalization. Patients using two drug classes at 50%-99% of the target dose have a lower risk compared to using one drug class at 100% of the target dose.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Review
Engineering, Biomedical
Jean Bonnemain, Pedro J. del Nido, Ellen T. Roche
Summary: The treatment of end-stage heart failure has undergone significant changes with advancements in medical treatment, cardiac transplantation, and mechanical circulatory support devices. However, current devices that come into direct contact with blood can lead to complications. The concept of compressing the failing heart from the epicardial surface and the design of direct cardiac compression devices have emerged as potential solutions.
ANNUAL REVIEW OF BIOMEDICAL ENGINEERING
(2022)
Article
Cardiac & Cardiovascular Systems
Parag Goyal, Lauren Balkan, Joanna B. Ringel, Scott L. Hummel, Madeline R. Sterling, Samuel Kim, Pankaj Arora, Elizabeth A. Jackson, Todd M. Brown, James M. Shikany, Suzanne E. Judd, Monika M. Safford, Emily B. Levitan
Summary: The study found that adherence to the DASH diet pattern was negatively associated with incident HF, specifically among individuals under 75 years old.
JOURNAL OF CARDIAC FAILURE
(2021)
Article
Cardiac & Cardiovascular Systems
Jasper Tromp, Wouter Ouwerkerk, John G. F. Cleland, Christiane E. Angermann, Ulf Dahlstrom, Katherine Tiew-Hwa Teng, Sahiddah Bamadhaj, Georg Ertl, Mahmoud Hassanein, Sergio Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Gerasimos Filippatos, Sean P. Collins, Carolyn S. P. Lam, Kenneth Dickstein
Summary: This study investigated global differences in prevalence, association with outcome, and treatment of ischemic heart disease (IHD) in patients with acute heart failure (AHF). It found that IHD was more common in low-income countries and was associated with higher 1-year mortality, especially in patients with heart failure with reduced ejection fraction (HFrEF). Patients in regions with the greatest burden of IHD were less likely to receive coronary revascularization and treatment for IHD.
JACC-HEART FAILURE
(2021)
Article
Cardiac & Cardiovascular Systems
Kashvi Gupta, Ioannis Mastoris, Andrew J. Sauer
HEART FAILURE CLINICS
(2024)
Review
Cardiac & Cardiovascular Systems
Alexander L. Wallner, Salvatore Savona, Rami Kahwash
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Muhammad Shahzeb Khan, Anousheh Awais Paracha, Jan Biegus, Rafael de la Espriella, Julio Nunez, Carlos G. Santos-Gallego, Dmitry Yaranov, Marat Fudim
Summary: The increase of preload in heart failure can lead to excessive intracardiac pressures. The reduction of preload can be achieved through pharmacological and nonpharmacological interventions, with nonpharmacological interventions aiming to reduce blood inflow or increase splanchnic vascular blood pooling.
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Parin J. Patel, Asim S. Ahmed
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Husam M. Salah, Claudia Baratto, Dmitry M. Yaranov, Karl-Philipp Rommel, Satyanarayana Achanta, Sergio Caravita, Vinay Kumar Reddy Vasanthu, Marat Fudim
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Gregory R. Jackson, Abhinav Singh
HEART FAILURE CLINICS
(2024)
Review
Cardiac & Cardiovascular Systems
Ronald D. Bass, Joseph Phillips, Jorge Sanz Sanchez, Priti Shah, Stephen Sum, Ron Waksman, Hector M. Garcia-Garcia
Summary: NIRS-derived LCBI is an effective measurement for identifying vulnerable patients and plaques at risk of future adverse events. Patients with an elevated LCBI have higher odds of enduring a future adverse event.
HEART FAILURE CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Adam Bland, Eunice Chuah, William Meere, Thomas J. Ford
Summary: CMD is a challenging condition to manage due to its heterogenous pathophysiology, presentation, and response to therapy. Although awareness of CMD is improving, there is a lack of randomized trials for therapy. Invasive assessment of the coronary microcirculation can improve patient-centered outcomes. Beta-blockers are the cornerstone of therapy for CMD angina, and non-pharmacological interventions play a central role in management. Further research is needed to assess the impact of traditional and novel pharmacological therapies on symptoms and clinical events in different CMD endotypes.
HEART FAILURE CLINICS
(2024)